Literature DB >> 14670023

Angioplasty and primary stenting of high-grade, long-segment superficial femoral artery disease: is it worthwhile?

Stephen W K Cheng1, Albert C W Ting, Pei Ho.   

Abstract

The purpose of this study was to determine the long-term results and efficacy of angioplasty and stenting of long-segment, high-grade superficial femoral artery disease. Seventy-three consecutive primary balloon angioplasty procedures with immediate stenting in 70 patients with SVS/ISCVS grade B2 or C superficial femoral artery (SFA) disease exceeding 5 cm in length were evaluated. The mean lesion length was 16 cm and occlusion constituted 62%, with a runoff score of 8. Forty-nine procedures (67%) were performed for critical ischemia. A total of 135 stents were placed. Follow-up was with 3-month duplex ultrasound; stenosis >50% was considered the end point for failure. Mean follow-up time was 26 months. Initial technical success with intent to treat was 90%. Initial success according to anatomic, hemodynamic, and clinical criteria was 90%, 88%, and 88%, respectively, with intent to treat. Limb salvage in the critical ischemia group was 71%. Overall cumulative primary patency rates at 12, 24, and 48 months were 56%, 35%, and 22%, and secondary patency rates were 69%, 47%, and 37%, respectively. A stented segment length >10 cm and procedure in claudicants incurred an inferior patency rate. Treatment of high-grade SFA lesions with angioplasty and primary setting results in lower long-term patency rate than those with surgery, but combined with secondary interventions this treatment option may be an acceptable alternative in selected patients with critical ischemia. Femoropopliteal bypass remains the procedure of choice.

Entities:  

Mesh:

Year:  2003        PMID: 14670023     DOI: 10.1007/s10016-003-0028-8

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  6 in total

1.  Ten years after arterial bypass surgery for claudication: venous bypass is the primary procedure for TASC C and D lesions.

Authors:  Thomas Eugster; Regula Marti; Lorenz Gurke; Peter Stierli
Journal:  World J Surg       Date:  2011-10       Impact factor: 3.352

Review 2.  Percutaneous treatment of peripheral vascular disease: the role of diabetes and inflammation.

Authors:  Louis L Nguyen
Journal:  J Vasc Surg       Date:  2007-06       Impact factor: 4.268

3.  Comparisons between prosthetic vascular graft and saphenous vein graft in femoro-popliteal bypass.

Authors:  Keun-Myoung Park; Young Wook Kim; Shin-Seok Yang; Dong-Ik Kim
Journal:  Ann Surg Treat Res       Date:  2014-06-24       Impact factor: 1.859

4.  The factors affecting recurrence of symptoms after infrainguinal arterial endovascular angioplasty.

Authors:  Mi Ju Bae; Jong Geun Lee; Sung Woon Chung; Chung Won Lee; Chang Won Kim
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2014-12-05

5.  Intravascular treatment of long segments of experimental peripheral arteries with multiple, serial, balloon-expandable, resorbable scaffolds.

Authors:  Rym El Khoury; Ivan Tzvetanov; Edward A Estrada; Edward McCarroll; Eugene Michal; Jack Blumeyer; Louis-Georges Guy; Martin Laflamme; Lewis B Schwartz
Journal:  JVS Vasc Sci       Date:  2022-03-28

6.  A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine.

Authors:  Ichiro Ikushima; Kazuchika Yonenaga; Hironao Iwakiri; Hideki Nagoshi; Haruhito Kumagai; Yasuyuki Yamashita
Journal:  Med Devices (Auckl)       Date:  2011-06-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.